Literature DB >> 15477517

Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence.

Jennifer Cavitt1, Michael Privitera.   

Abstract

BACKGROUND: Levetiracetam (LEV) is a new antiepileptic drug with efficacy in partial-onset seizures. We report a case in which generalized-onset absence seizures responded clinically and electrographically to LEV.
METHODS: We evaluated with continuous video/electroencephalography an adult with generalized-onset seizures given 3 antiepileptic drugs, 1 of which was LEV. Levetiracetam initiation 2 months before admission decreased patient-reported seizures. Interictal electroencephalography revealed generalized 3.5-Hz spike-wave and polyspike-wave discharges. Spike-wave bursts lasting 2 seconds or longer caused a pause in continuous reading aloud, consistent with clinical absence seizures. Levetiracetam was discontinued on admission, lamotrigine was gradually discontinued across 2 days, and topiramate was not changed. One encephalographer counted from video/electroencephalography recordings the number of spike-wave bursts in 1-hour time samples that included wake and sleep time.
RESULTS: Spike-wave bursts increased from 4 to 56 per hour at baseline (4000 mg of LEV per day) to 406 to 914 per hour less than 48 hours after LEV discontinuation. Levetiracetam treatment was restarted, and 3 hours after the first dose of 1000 mg, spike-wave bursts dropped to 135 per hour. Response was sustained during the next 2 days.
CONCLUSIONS: This case showed a dramatic, rapid effect of LEV discontinuation and reinstitution on generalized spike-wave burst frequency and clinical absence. The effects were independent of reduction of lamotrigine and without change in topiramate doses and occurred in a time course consistent with LEV pharmacokinetics. Levetiracetam may be effective in generalized-onset epilepsy, and randomized, controlled trials are indicated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477517     DOI: 10.1001/archneur.61.10.1604

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  4 in total

1.  Valproate efficacy in absence seizures is hard to beat: lamotrigine comes close.

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2005 Mar-Apr       Impact factor: 7.500

2.  Levetiracetam efficacy in idiopathic generalized epilepsy: long suspected and now confirmed in randomized clinical trials.

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2008 Jan-Feb       Impact factor: 7.500

Review 3.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Real-Time Monitoring of Levetiracetam Effect on the Electrophysiology of an Heterogenous Human iPSC-Derived Neuronal Cell Culture Using Microelectrode Array Technology.

Authors:  Andrea Di Credico; Giulia Gaggi; Pascal Izzicupo; Laura Ferri; Laura Bonanni; Giovanni Iannetti; Angela Di Baldassarre; Barbara Ghinassi
Journal:  Biosensors (Basel)       Date:  2021-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.